NCT07364786 Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
| NCT ID | NCT07364786 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Peter Siesjö |
| Condition | Glioblastoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-10-07 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 10 participants in total. It began in 2024-10-07 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.
Eligibility Criteria
Inclusion Criteria: 1. Suspected glioblastoma 2. Age 18-75 years 3. Planned diagnostic biopsy 4. Informed consent of subject Exclusion Criteria: 1\. Known egg yolk allergy
Contact & Investigator
Peter Siesjö, MD, PhD
PRINCIPAL INVESTIGATOR
Skane University Hospital
Frequently Asked Questions
Who can join the NCT07364786 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Glioblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07364786 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07364786 currently recruiting?
Yes, NCT07364786 is actively recruiting participants. Contact the research team at peter.siesjo@skane.se for enrollment information.
Where is the NCT07364786 trial being conducted?
This trial is being conducted at Lund, Sweden.
Who is sponsoring the NCT07364786 clinical trial?
NCT07364786 is sponsored by Peter Siesjö. The principal investigator is Peter Siesjö, MD, PhD at Skane University Hospital. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.